Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 1:57 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1057–1080 of 3,083 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Surgical Management Clear all

Conditions: Arthroplasties, Knee Replacement
Interventions: Inelastic adjustable compression garment (INCOM), Elastic compression garment (CONTROL); Other
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 50 Years to 120 Years
Enrollment: 58 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2026
U.S. locations: 2
States / cities: Aurora, Colorado • Denver, Colorado

Conditions: Ovarian Neoplasm, Uterine Neoplasm
Interventions: Informational Intervention, Questionnaire Administration, Telephone-Based Intervention; Other · Behavioral
Lead sponsor: Wake Forest University Health Sciences; Other
Eligibility: 18 Years and older · Female only
Enrollment: 31 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 1
States / cities: Winston-Salem, North Carolina

Conditions: Duchenne Muscular Dystrophy
Interventions: VECTTOR; Device
Lead sponsor: Alan Neuromedical Technologies, LLC; Industry
Eligibility: 8 Years to 20 Years
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Advanced Parkinson's Disease
Interventions: Levodopa carbidopa intestinal gel (LCIG), Placebo gel, Levodopa carbidopa (LC) oral encapsulated immediate release (IR) tablets, Placebo (PBO) oral capsules, CADD-Legacy® 1400 ambulatory infusion pump, PEG tube, J-tube; Drug · Device
Lead sponsor: AbbVie (prior sponsor, Abbott); Industry
Eligibility: 30 Years and older
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2011
U.S. locations: 8
States / cities: Los Angeles, California • Englewood, Colorado • Washington D.C., District of Columbia + 5 more

Conditions: Stage 0is Bladder Urothelial Carcinoma, Stage I Bladder Urothelial Carcinoma, Stage II Bladder Urothelial Carcinoma, Stage III Bladder Urothelial Carcinoma
Interventions: Questionnaire Administration, Radical Cystectomy; Other · Procedure
Lead sponsor: University of Southern California; Other
Eligibility: Not listed
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Venous Thrombosis Deep (Limbs), Surgical Blood Loss
Interventions: Enoxaparin Injectable Product, Sodium chloride; Drug
Lead sponsor: Valleywise Health; Other
Eligibility: 18 Years and older
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2023
U.S. locations: 1
States / cities: Phoenix, Arizona

Conditions: Postoperative Pain
Interventions: HTX-011, Bupivacaine HCl, Saline placebo, Luer-lock applicator, Vial access device; Drug · Device
Lead sponsor: Heron Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 418 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 22
States / cities: Florence, Alabama • Sheffield, Alabama • Phoenix, Arizona + 18 more

Conditions: Prostate Adenocarcinoma, Stage I Prostate Cancer American Joint Committee on Cancer (AJCC) v8, Stage II Prostate Cancer AJCC v8, Stage IIA Prostate Cancer AJCC v8, Stage IIB Prostate Cancer AJCC v8, Stage IIC Prostate Cancer AJCC v8
Interventions: Discussion, Hypofractionated Radiation Therapy, Laboratory Biomarker Analysis, Quality-of-Life Assessment, Questionnaire Administration, Stereotactic Body Radiation Therapy; Procedure · Radiation · Other
Lead sponsor: Jonsson Comprehensive Cancer Center; Other
Eligibility: 18 Years and older · Male only
Enrollment: 208 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2028
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Lymphoma, Non-Hodgkin Lymphoma, NHL, Hematologic Malignancies, Lymphoid Malignancies
Interventions: Vysis LSI MYC Break Apart Rearrangement Probe Kit, Venetoclax, VIP152, Prednisone, PET, EKG, ECHO, CT neck chest, abdomen, and pelvis, MRI, Bone marrow aspiration/Biopsy; Device · Drug · Diagnostic Test + 1 more
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Cardiac Disease, Bleeding Postoperative
Interventions: Fresh Autologous whole Blood, Standard of Care Expectant management of bleeding; Other
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 18 Years to 90 Years
Enrollment: 70 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 1
States / cities: Aurora, Colorado

Conditions: Pain, Pituitary Surgery
Interventions: Oxytocin (Low dose), Oxytocin (High dose), Placebo (saline); Drug
Lead sponsor: Yale University; Other
Eligibility: 30 Years to 75 Years
Enrollment: 75 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Diabetes
Interventions: Not listed
Lead sponsor: NYU Langone Health; Other
Eligibility: 18 Years to 80 Years
Enrollment: 55 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 1
States / cities: New York, New York

Conditions: Ambulatory Hand Surgery
Interventions: Patient education regarding indications for opioid use and side effects of opioid use after hand surgery, Standard of care post-operative counseling; Behavioral · Other
Lead sponsor: Hospital for Special Surgery, New York; Other
Eligibility: 18 Years and older
Enrollment: 400 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2022
U.S. locations: 1
States / cities: New York, New York

Conditions: Tonsillectomy
Interventions: Honey, Standard of Care; Dietary Supplement · Other
Lead sponsor: Vanderbilt University Medical Center; Other
Eligibility: 5 Years to 17 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Locally Advanced Unresectable Pancreatic Ductal Adenocarcinoma, Stage II Pancreatic Cancer AJCC v8, Stage III Pancreatic Cancer AJCC v8, Stage IV Pancreatic Cancer AJCC v8
Interventions: Biopsy Procedure, Biospecimen Collection, Capecitabine, Computed Tomography, Dose-escalated Radiation Therapy, Fluorouracil, Gemcitabine, Irinotecan Hydrochloride, Irinotecan Sucrosofate, Leucovorin Calcium, Magnetic Resonance Imaging, Nab-paclitaxel, Observation Activity, Oxaliplatin, Positron Emission Tomography, Questionnaire Administration, Radiation Therapy, Tumor Treating Fields Therapy; Procedure · Drug · Radiation + 1 more
Lead sponsor: NRG Oncology; Other
Eligibility: 18 Years and older
Enrollment: 356 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2030
U.S. locations: 332
States / cities: Gilbert, Arizona • Peoria, Arizona • Phoenix, Arizona + 252 more

Conditions: Colorectal Cancer
Interventions: Accelerated Recovery Plan, Early Discharge, Telemedicine, Standard Enhanced Care; Behavioral · Other
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years to 79 Years
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2022
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Intracranial Surgery
Interventions: PCA fentanyl, PRN fentanyl; Drug
Lead sponsor: Johns Hopkins University; Other
Eligibility: 18 Years and older
Enrollment: 159 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2010
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Appendicitis
Interventions: Not listed
Lead sponsor: Peter Minneci; Other
Eligibility: 7 Years to 17 Years
Enrollment: 102 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2023
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: Metastatic Differentiated Thyroid Gland Carcinoma, Metastatic NUT Carcinoma, Metastatic Thyroid Gland Anaplastic Carcinoma, Metastatic Thyroid Gland Medullary Carcinoma, Refractory Differentiated Thyroid Gland Carcinoma, Stage III Differentiated Thyroid Gland Carcinoma AJCC v8, Stage III Thyroid Gland Medullary Carcinoma AJCC v8, Stage IV Differentiated Thyroid Gland Carcinoma AJCC v8, Stage IV Thyroid Gland Medullary Carcinoma AJCC v8, Unresectable Differentiated Thyroid Gland Carcinoma, Unresectable NUT Carcinoma, Unresectable Thyroid Gland Anaplastic Carcinoma, Unresectable Thyroid Gland Medullary Carcinoma
Interventions: Biopsy Procedure, Biospecimen Collection, Computed Tomography, Enfortumab Vedotin, Magnetic Resonance Imaging, Survey Administration, X-Ray Imaging; Procedure · Drug · Other
Lead sponsor: Northwestern University; Other
Eligibility: 18 Years and older
Enrollment: 56 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2027 – 2031
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Rectal Adenocarcinoma, Stage II Rectal Cancer AJCC v8, Stage IIA Rectal Cancer AJCC v8, Stage IIB Rectal Cancer AJCC v8, Stage IIC Rectal Cancer AJCC v8, Stage III Rectal Cancer AJCC v8, Stage IIIA Rectal Cancer AJCC v8, Stage IIIB Rectal Cancer AJCC v8, Stage IIIC Rectal Cancer AJCC v8
Interventions: Chemotherapy, Patient Observation, Questionnaire Administration, Resection of Rectum; Drug · Other · Procedure
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Confirmed Biallelic RPE65 Mutation-associated Retinal Dystrophy
Interventions: AAV2-hRPE65v2,voretigene neparvovec-rzyl; Biological
Lead sponsor: Spark Therapeutics, Inc.; Industry
Eligibility: 12 Months and older
Enrollment: 87 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2025
U.S. locations: 10
States / cities: Los Angeles, California • Miami, Florida • Iowa City, Iowa + 6 more

Conditions: Acute Myeloid Leukemia, Graft Versus Host Disease, Myelodysplastic Syndrome
Interventions: Biospecimen Collection, Busulfan, Computed Tomography, Cyclophosphamide, Echocardiography Test, Emapalumab, Fludarabine, Hematopoietic Cell Transplantation, Melphalan, Multigated Acquisition Scan, Mycophenolate Mofetil, Questionnaire Administration, Tacrolimus; Procedure · Drug · Biological + 1 more
Lead sponsor: City of Hope Medical Center; Other
Eligibility: 18 Years to 75 Years
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Duarte, California

Conditions: Endotracheal Intubation, Rapid Airway Management Positioner
Interventions: Laryngoscopy with RAMP, Laryngoscopy without RAMP; Device
Lead sponsor: The University of Texas Health Science Center, Houston; Other
Eligibility: 18 Years to 80 Years
Enrollment: 51 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Cardiovascular Disease
Interventions: EVARREST™, Topical hemostat, Standard of Care; Biological · Other
Lead sponsor: Ethicon, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 42 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 6
States / cities: Indianapolis, Indiana • Kansas City, Missouri • Camden, New Jersey + 2 more

Search by objective public record fields.

Swelling Management After Knee Replacement

Supportive Programs for Supporting Optimal Recovery in Participants Undergoing Gynecological Surgery

Duchenne Muscular Dystrophy Clinical Trial

Study of Efficacy, Safety and Tolerability of Levodopa-Carbidopa Intestinal Gel in Levodopa-Responsive Parkinson's Subjects

Robotic or Open Radical Cystectomy in Treating Patients With Bladder Cancer

Pre-operative Enoxaparin in the Surgical Management of Multi-trauma Patients Undergoing Orthopedic Surgical Procedures

Phase 3 Herniorrhaphy Study for Postoperative Analgesia (EPOCH 2)

Germline DNA-Based Radiosensitivity Biomarker Influence on Toxicity Following Prostate Radiotherapy, GARUDA Trial

Study of VIP152, Venetoclax, and Prednisone (VVIP) in Relapsed/Refractory Lymphoid Malignancies

Fresh Autologous Whole Blood Transfusion After Cardiopulmonary Bypass

Evaluating Intranasal Oxytocin (TNX-1900) for Pain Relief and Recovery After Pituitary Surgery

Comparative Effectiveness of Bariatric Surgery Versus Medical Management to Induce Diabetes Remission in Diabetic Patients With BMI 30-35

Patient Education and Use of Post Operative Pain Medication in Ambulatory Hand Surgery: a Randomized Controlled Trial

Here's the Buzz: Evaluating Pediatric Post Op Pain and Nausea Following Tonsillectomy Surgery

Testing Higher Dose Radiation Therapy for Locally Advanced Pancreatic Cancer

Accelerated Enhanced RECOVERy Following Minimally Invasive Colorectal Cancer Surgery (RecoverMI)

IVPCA in the Management of Pain Following Major Intracranial Surgery

Non-operative Management of Early Appendicitis in Children

Enfortumab Vedotin for the Treatment of Unresectable or Metastatic Radioiodine Refractory Differentiated Thyroid Cancer, Anaplastic Thyroid Cancer, Medullary Thyroid Cancer, or NUT Carcinoma

Active Surveillance and Chemotherapy Before Surgery in Treating Participants With Stage II-III Rectal Cancer

A Patient Registry Study for Patients Treated With Voretigene Neparvovec in US

Emapalumab With Post-Transplant Cyclophosphamide, Tacrolimus and Mycophenolate Mofetil for the Prevention of Graft-versus-Host Disease After Donor Reduced-Intensity Hematopoietic Cell Transplant

Evaluation of the Rapid Airway Management Positioner

The Fibrin Pad Cardiovascular Study